Literature DB >> 1379707

The trigemino-vascular system and migraine.

M G Buzzi1, M A Moskowitz.   

Abstract

Neurogenic inflammation has been proposed as a possible pathogenetic mechanism for migraine and cluster headache. Antidromic stimulation of trigeminal fibers causes plasma protein extravasation, mast cell activation and degranulation, vacuolation and increase in endothelial vesicle number within post capillary venules in rat dura mater. The antimigraine drugs sumatriptan and dihydroergotamine block the development of plasma extravasation and ultrastructural changes, as well as plasma calcitonin gene-related peptide (CGRP) increase in the superior sagittal sinus following electrical trigeminal ganglion stimulation. Sumatriptan and dihydroergotamine bind with high affinity to the 5-HT1D/1B receptors, thus suggesting that their neurogenic antiinflammatory activity is mediated by activation of 5-HT autoreceptors present on sensory fibers innervating blood vessels in dura mater.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379707

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  23 in total

1.  Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide.

Authors:  Thomas Denekas; Markus Tröltzsch; Axel Vater; Sven Klussmann; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment.

Authors:  Erika Fh Saunders; Aubrey Reider; Gagan Singh; Alan J Gelenberg; Stanley I Rapoport
Journal:  Bipolar Disord       Date:  2015-10-01       Impact factor: 6.744

Review 3.  Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

4.  Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan.

Authors:  J E Jayamaha; M K Street
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

5.  Reconsidering Dietary Polyunsaturated Fatty Acids in Bipolar Disorder: A Translational Picture.

Authors:  Erika F H Saunders; Christopher E Ramsden; Mostafa S Sherazy; Alan J Gelenberg; John M Davis; Stanley I Rapoport
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

6.  Repression of calcitonin gene-related peptide expression in trigeminal neurons by a Theobroma cacao extract.

Authors:  Marcie J Abbey; Vinit V Patil; Carrie V Vause; Paul L Durham
Journal:  J Ethnopharmacol       Date:  2007-10-05       Impact factor: 4.360

Review 7.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 8.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

9.  CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

Authors:  J Zeller; K T Poulsen; J E Sutton; Y N Abdiche; S Collier; R Chopra; C A Garcia; J Pons; A Rosenthal; D L Shelton
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

Review 10.  Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.

Authors:  Peer Tfelt-Hansen; Karl Messlinger
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.